- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Metastatic colorectal cancer (mCRC)
- Meeting Date: September 2024
- Public Summary Document (PSD) September 2024 PBAC Meeting - (PDF 887KB)
- Public Summary Document (PSD) September 2024 PBAC Meeting - (Word 334KB)
Fruquintinib – September 2024
Fruquintinib: Capsule 1 mg, Capsule 5 mg; Fruzaqla®
Last updated
30 May 2025